ABSTRACT Introduction: The Glanzmann Thrombasthenia (GT) and Bernard-Soulier Syndrome (BSS) are rare hereditary disorders of platelet function. Their treatment often requires platelet transfusion, which can lead to the development of alloantibodies. Objective: In this study, we aim to develop a strategy for alloantibody detection and to describe the frequency of alloimmunization in a patient population from a single center in southeastern Brazil. Methods: Samples from patients with GT or BSS were tested using the Platelet Immunofluorescence Test (PIFT). If a positive result was obtained, a confirmatory step using the Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) and Luminex bead-based platelet assay (PAKLx) was executed. Main results: Among 11 patients with GT, we detected the presence of alloantibodies in 5 using PIFT, with confirmation through MAIPA and PAKLx in 2 (1 anti-HLA and 1 anti-HPA), resulting in a frequency of 18.1%. Among 4 patients with BSS, PIFT was positive in 3, with confirmation by MAIPA and PAKLx in 1 (anti-HLA), showing a frequency of 25%. The two patients with anti-HLA antibodies exhibited a panel reactive antibody (PRA-HLA) testing greater than 97%. Conclusion: Our study highlights the importance of identifying platelet alloimmunization in this patient population. The proposed algorithm for platelet alloantibodies detection allows resource optimization. Introduction (GT BernardSoulier Bernard Soulier (BSS function transfusion Objective Brazil Methods PIFT. . (PIFT) obtained (MAIPA beadbased bead based (PAKLx executed results ( antiHLA anti HLA antiHPA, antiHPA HPA , anti-HPA) 181 18 18.1% 3 antiHLA, (anti-HLA) 25 25% PRAHLA PRA (PRA-HLA 97 97% Conclusion optimization (PIFT anti-HPA 18.1 (anti-HLA 9 18.

BACKGROUND: Experimental data have shown that the transfusion of older red blood cell units causes alloimmunization, but the clinical applicability of this statement has never been properly assessed in non-sickle cell patients. It has been hypothesized that older units have higher numbers of cytokines, increasing the risk of alloimmunization related to antigen-presenting events. The goal of this study was to evaluate the association between the transfusion of older red blood cell units subjected to bedside leukodepletion and alloimmunization.METHODS: All patients submitted to transfusions of bedside leukodepletion red blood cell units proven to have become alloimmunized in one oncologic service between 2009 and 2013 were enrolled in this study. A control group was formed by matching patients without alloimmunization in terms of number of transfusions and medical specialty. The median age of transfused units, the percentage of transfused red blood cell units >14 days of storage in relation to fresher red cell units (≤14 days of storage) and the mean age of transfused units older than 14 days were compared between the groups.RESULTS: Alloimmunized and control groups were homogeneous regarding the most relevant clinical variables (age, gender, type of oncological disease) and inflammatory background (C-reactive protein and Karnofsky scale). The median age of transfused red blood cell units, the ratio of older units transfused compared to fresher units and the mean age of transfused units older than 14 days did not differ between alloimmunized and control patients (17 vs. 17; 68/32 vs. 63.2/36.8 and 21.8 ± 7.0 vs. 21.04 ± 7.9; respectively).CONCLUSION: The transfusion of older red blood cell units subjected to bedside leukodepletion is not a key risk factor for alloimmunization. Strategies of providing fresh red cell units aiming to avoid alloimmunization are thus not justified.

Blood transfusion safety is a critical part of appropriate health care. Considering the limited information available on the use of blood and its components in Latin America and the Caribbean, the Grupo Cooperativo iberoamericano de Medicina Transfusional (Ibero-American Cooperative Group for Transfusion Medicine; GCIAMT), through its Research and International Affairs committees, carried out a project to develop a protocol that would facilitate the evaluation of blood usage at the country, jurisdiction, and institutional levels in varied country contexts. Experts in blood safety from the Pan American Health Organization (Washington, DC, United States), the University of São Paulo (São Paulo, Brazil), the Hemocentro of São Paulo (São Paulo, Brazil), and GCIAMT designed a 2-step comprehensive blood-use evaluation protocol: step 1 collects data from blood requests, and step 2, from medical charts. At a minimum, 1 000 analyzed requests are necessary; as such, study periods vary depending on the number of transfusion requests issued. An Internet-based application, the Modular Research System-Study Management System (MRS-SMS), houses the data and produces reports on how hospitals request blood, how blood is issued, who requires blood and blood components, and as an added benefit, how many blood units are wasted and what the real demand for blood is.

La seguridad de las transfusiones de sangre constituye una parte fundamental de una apropiada atención de salud. Teniendo en cuenta la limitada información disponible sobre el uso de la sangre y sus componentes en América Latina y el Caribe, el Grupo Cooperativo Iberoamericano de Medicina Transfusional (GCIAMT), mediante sus comités de Investigación y de Asuntos Internacionales, llevó a cabo un proyecto de elaboración de un protocolo que facilitara la evaluación del uso de la sangre a nivel de país, jurisdiccional e institucional, en diversos contextos de país. Expertos en seguridad de la sangre de la Organización Panamericana de la Salud (Washington, DC, Estados Unidos), la Universidad de São Paulo (São Paulo, Brasil), el Hemocentro de São Paulo (São Paulo, Brasil) y el GCIAMT diseñaron un protocolo integral de evaluación del uso de la sangre en 2 etapas: en la primera se recopilan datos de las solicitudes de sangre, y en la segunda, de las historias clínicas. Como mínimo, es preciso analizar 1 000 solicitudes; por ello, los períodos de estudio varían en dependencia del número de solicitudes de transfusión expedidas. Una aplicación basada en internet, el Modular Research System, Study Management System, alberga los datos y elabora informes sobre cómo solicitan sangre los hospitales, cómo se expide la sangre, quién requiere sangre y componentes sanguíneos y, como beneficio añadido, cuántas unidades de sangre se desperdician y cuál es la demanda real de sangre.